Supplementary Materials

Cytotoxicity and antibacterial activities of a group of amicoumacins from a marine-derived bacterium *Bacillus subtilis*

Yongxin Li¹, Ying Xu¹, Lingli Liu¹, Zhuang Han¹, Pok Yui Lai¹, Xiangrong Guo², Xixiang Zhang², Wenhan Lin³, Pei-Yuan Qian^{1,*}

- ¹ KAUST Global Collaborative Research, Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong; E-mail: liyongxin@ust.hk (Y.L.); boxuying@ust.hk (Y.X.); leonie@ust.hk (L.L.); zhuanghan@ust.hk (Z.H.); cycylai@ust.hk (P.Y.L.);
- ² King Abdullah University of Science and Technology, Saudi Arabia;
 E-mail: xianrong.guo@kaust.edu.sa (X.G.); xixiang.zhang@kaust.edu.sa (X.Z.)
- ³ State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, P.R. China; E-mail: whlin@bjmu.edu.cn
- * Author to whom correspondence should be addressed; E-Mail: boqianpy@ust.hk; Tel.: + -852- 2358-7331; Fax: +852- 2358-1559

	Supp	orting information 1	
Table-1	NMR data of lipoamicoumacins A-D (1-4)	2	
Table-2	NMR data of bacilosarcin C (5) and bacilosarcin B (6)	3	

	1				2		3			4	
position	δ _C , mult	$\delta_{\rm H}$, (<i>J</i> in Hz)	HMBC	δ_{C} , mult	$\delta_{\rm H}$, (<i>J</i> in Hz)	δ_{C} , mult	$\delta_{\rm H}$, (J in Hz)	HMBC	δ _C , mult	$\delta_{\rm H}$, (J in Hz)	
1	171.2. C			171.2. C		171.2, C			171.2. C		
3	82.7, CH	4.68, m	1	82.7, CH	4.68, m	82.7, CH	4.69, dt (11.0, 3.8)	1	82.7, CH	4.69, dt (11.0, 3.8)	
4	30.8, CH ₂	2.98, dd (3.5, 16.0), 3.06, m	5, 9, 10	31.0, CH ₂	2.98, m, 3.06, m	30.8, CH ₂	2.98, dd (3.5, 16.0), 3.06, m	5, 9, 10	30.8, CH ₂	2.98, dd (3.5, 16.0) 3.06, m	
5	119.8, CH	6.81, d (7.6)	4, 7, 9	119.8, CH	6.81, d (7.4)	119.8, CH	6.81, d (7.5)	4, 7, 9	119.8, CH	6.82, d (7.8)	
6	137.8, CH	7.47, dd (7.5, 8.4)	8, 10	137.8, CH	7.47, dd (7.4, 8.6)	137.8, CH	7.47, dd (7.5, 8.4)	8, 10	137.8, CH	7.47, t (7.9)	
7	116.9, CH	6.85, d (8.4)	5, 8, 9,	116.9, CH	6.85, d (8.6)	117.0, CH	6.85, d (8.4)	5, 8, 9,	116.9, CH	6.85, d (8.0)	
8	163.3, C			163.3, C		163.3, C			163.3, C		
9	109.6, C			109.6, C		109.6, C			109.6 , C		
10	141.4, C			141.4, C		141.5, C			141.4, C		
1'	22.1, CH ₃	0.89, d (6.6)	2', 4'	22.1, CH ₃	0.89, d (6.6)	22.1, CH ₃	0.89, d (6.6)	2', 4'	22.2, CH ₃	0.89, d (6.6)	
2'	24.0, CH ₃	0.97, d (6.6)	1', 4'	23.9, CH ₃	0.97, d (6.6)	24.0, CH ₃	0.97, d (6.6)	1', 4'	24.0, CH ₃	0.97, d (6.6)	
3'	26.0, CH	1.68, m		25.9, CH	1.68, m	26.0, CH	1.68, m		25.9, CH	1.68, m	
4'	40.4, CH ₂	1.43, m, 1.82, m		40.4, CH ₂	1.43, m, 1.82, m	40.7, CH ₂	1.43, m, 1.82, m		40.7, CH ₂	1.44, m, 1.84, m	
5'	50.7, CH	4.29, m	7'	50.7, CH	4.29, m	50.7, CH	4.29, m	7'	50.7, CH	4.28, m	
7'	172.8, C			172.8, C		172.8, C			172.8, C		
8'	73.6, CH	4.42, d (2.5)	7', 10'	73.7, CH	4.42, d (2.5)	73.6, CH	4.42, d (2.5)	7', 10'	73.6, CH	4.42, d (2.3)	
9'	87.9, CH	4.79, t (2.4)	7', 12'	87.9, CH	4.78, t (2.4)	87.9, CH	4.79, t (2.4)	7', 12'	87.8, CH	4.79, t (2.2)	
10'	48.6, CH	4.51, dt (9.1, 2.0)	14'	48.6, CH	4.51, m	48.6, CH	4.51, dt (9.1, 2.0)	14'	48.6, CH	4.51, dt (9.2, 2.0)	
11'	36.7, CH ₂	2.45, dd (2.6, 18.0) , 3.01 m	12'	36.7, CH ₂	2.46, dd (2.7, 18.2), 3.01, m	37.0, CH ₂	2.42, dd (2.7, 18.2), 3.03, m	12'	37.0, CH ₂	2.42, dd (2.6, 18.3), 3.02, m	
12'	178.1, C			178.2, C		178.1, C			178.1, C		
Asparagir	e or Glutamine	2									
14'	173.3, C			173.3, C		173.9, C			173.8, C		
15'	51.3, CH	4.65,dd (6.5, 7.0)	14', 1"	51.5, CH	4.65, t (6.6)	52.4, CH	4.30, m	14', 1"	52.4, CH	4.30, m	
16'	38.2, CH ₂	2.57 dd (7.1, 15.2), 2.67, dd (6.4,15.2)	14', 17'	37.9, CH ₂	2.57, dd (7.0, 15.4), 2.67, dd (6.4,15.4)	29.2, CH ₂	1.86, m, 2.00, m	14', 18'	29.1, CH ₂	1.88, m, 2.01, m	
17'	174.8, C			174.8, C		32.6, CH ₂	2.25, m	18'	32.6, C	2.26, m	
18'						177.9, C			177.8, C		

 Table 1.
 NMR data of lipoamicoumacins A–D (1–4)

					Table 1. Cont					
Fatty acid	1									
1"	176.3, C			176.2, C		176.5, C			176.5, C	
2"	37.0, CH ₂	2.24 t (8.0)	1"	37.1, CH ₂	2.21 t (8.1)	37.1, CH ₂	2.24, t (8.0)	1"	37.0 , CH_2	2.23 t (8.0)
3"	27.0, CH ₂	1.60, m		26.8, CH ₂	1.59, m	27.0, CH ₂	1.60, m		27.0, CH ₂	1.60, t
4"~8"	30.5-31.2,			30.5-31.2		30.5-31.2			30.5-31.2,	
9"	38.3, CH ₂	1.17 m, 1.30 m		35.8, CH ₂	1.30 m	40.4, CH ₂	1.18, m, 1.27, m		35.8, CH ₂	1.30 m
10"	27.0, CH	1.53 m		28.3, CH	1.29 m	29.5, CH ₃	1.53, m		28.3, CH ₂	1.29, m
11"	23.2, CH ₃	0.88, t (6.8)	9"	37.9, CH ₃	1.10 m, 1.30 m	23.2, CH ₃	0.88, t (6.8)	9"	37.9, CH ₂	1.10 m, 1.30 m
12"	23.2, CH ₃	0.88, t (6.8)	9"	11.9, CH ₃	0.88, t (6.8)	23.2, CH ₃	0.88, t (6.8)	9"	11.9, CH ₂	0.88, t (6.8)
13"				19.8, CH ₃	0.86, d (6.4)				19.8, CH ₃	0.86, d (6.5)

Table 2. NMR data of bacilosarcin C (5) and bacilosarcin B (6) in CD₃OD

		5		6			5		6
position	δ_C mult	$\delta_{\rm H}$, (J in Hz)	HMBC	$\delta_{\rm H}$, (J in Hz)	position	δ_C mult	$\delta_{\rm H}$, (J in Hz)	HMBC	$\delta_{\rm H}$, (J in Hz)
1	171.0 C				4'	40.3, CH ₂	1.46, m, 1.80, m	5'	1.46, m, 1.80, m
3	82.5, CH	4.66, dt (3.5, 12.0)	1,	4.67, dt (3.4, 12.0)	5'	50.4, CH	4.34, dt (10.9, 3.9)	7'	4.34, dt (10.9, 3.9)
4	30.8, CH ₂	2.96, dd (3.5, 16.5)	3, 5, 9, 10	2.96, dd (3.5, 16.5	7'	173.5, C			
		3.10, dd (16.5, 12.0)	3, 5, 10	3.11, dd (16.5, 12.0	8'	71.9, CH	4.14, d (7.8)	7'	4.11, d (7.9)
5	119.6, CH	6.81, d (7.5)	4, 7, 9	6.81, d (7.5)	9'	68.9, CH	4.68, dd (3.0, 8.0)	7', 11', 15'	4.65, dd (3.1, 8.5)
6	137.5, CH	7.46, dd (7.5, 8.4)	8, 10	7.46, dd (7.5, 8.4)	10'	51.8, CH	3.91, m		3.82, m
7	116.7, CH	6.85, d (8.4)	5, 8, 9,	6.85, d (8.4)	11'	28.8, CH ₂	2.92, dd (8.5, 16.5)	12'	2.93, dd (7.5, 18.0)
8	163.1, C						3.06, dd (16.5, 4.0)	12'	2.86, dd (17.5, 3.5)
9	109.3, C				12'	174.4, C			
10	141.2, C				13'	13.9, CH ₃	1.28, d (6.5)	15'	1.28, d (6.5)
1'	21.7, CH ₃	0.94, d (6.5)	2', 4'	0.94, d (6.5	14'	53.0, CH	3.43, q (6.4)	10', 15'	3.47, q (6.5)
2'	23.7, CH ₃	0.98, d (6.5)	1', 4'	0.98, d (6.5	15'	96.2, C			
3'	25.9, CH ₂	1.71, m		1.69, m	16'	24.8, CH ₃	1.26 s	14'	

compound		Cytotoxicity (IC ₅₀ , µM)		
compound	Bacllus subtillis	Staphylococcus aureus	Loktanella hongkongensis	Hela
1	^a NA	NA	NA	NA
2	NA	NA	NA	NA
3	NA	NA	NA	NA
4	NA	NA	NA	NA
5	NA	NA	NA	NA
6	NA	4.05	16.19	33.60
7	18.87	18.87	1.18	4.32
8	NA	NA	NA	NA
9	NA	NA	NA	NA
10	NA	NA	NA	NA
11	NA	NA	NA	NA
Penicilin G	0.29	0.73	5.81	
cis-DDP				15.87

Table 3. Antibacterial activities and cytotoxicity of amicoumacin derivate	es
--	----

^aNA: MIC>100 μ M (antibacterial) or IC₅₀>100 μ M (cytotoxicity)

Cytotoxicity and antibacterial activities of a group of amicoumacins from a marine-derived bacterium *Bacillus subtilis*

Yongxin Li¹, Ying Xu¹, Lingli Liu¹, Zhuang Han¹, Pok Yui Lai¹, Xiangrong Guo², Xixiang Zhang², Wenhan Lin³, Pei-Yuan Qian¹*

- ¹ KAUST Global Collaborative Research, Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong; E-mail: liyongxin@ust.hk (Y. L.); boxuying@ust.hk (Y. X.); leonie@ust.hk (L. L.); zhuanghan@ust.hk (Z. H.); cycylai@ust.hk (P. Y. L.);
- ² King Abdullah University of Science and Technology, Saudi Arabia; E-mail: xianrong.guo@kaust.edu.sa (X. G.); xixiang.zhang@kaust.edu.sa (X. Z.)
- ³ State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, P.R. China; E-mail: whlin@bjmu.edu.cn
- * Author to whom correspondence should be addressed; E-Mail: boqianpy@ust.hk; Tel.: + -852- 2358-7331; Fax: +852- 2358-1559

Fig 1-1	¹ H NMR spectrum of 1	4
Fig 1-2	DEPT spectrum of 1	4
Fig 1-3	COSY spectrum of 1	5
Fig 1-4	HMQC spectrum of 1	5
Fig 1-5	HMBC spectrum of 1	6
Fig 1-6	NOESY spectrum of 1	6
Fig 1-7	CD spectrum of 1	7
Fig 1-8	IR spectrum of 1	7
Fig 1-9	HRESIMS spectrum of 1	8
Fig 1-10	ESIMS spectrum of 1	8
Fig 2-1	¹ H NMR spectrum of 2	9
Fig 2-2	DEPT spectrum of 2	9
Fig 2-3	COSY spectrum of 2	10
Fig 2-4	HMQC spectrum of 2	10
Fig 2-5	HMBC spectrum of 2	11
Fig 2-6	NOESY spectrum of 2	11
Fig 2-7	CD spectrum of 2	12
Fig 2-8	IR spectrum of 2	12
Fig 2-9	HRESIMS spectrum of 2	13
Fig 2-10	ESIMS spectrum of 2	13
Fig 3-1	¹ H NMR spectrum of 3	14
Fig 3-2	DEPT spectrum of 3	14
Fig 3-3	COSY spectrum of 3	15
Fig 3-4	HMQC spectrum of 3	15
Fig 3-5	HMBC spectrum of 3	16
Fig 3-6	IR spectrum of 3	16
Fig 3-7	CD spectrum of 3	17
Fig 3-8	HRESIMS spectrum of 3	17
Fig 3-9	ESIMS spectrum of 3	17
Fig 4-1	¹ H NMR spectrum of 4	18
Fig 4-2	DEPT spectrum of 4	18
Fig 4-3	COSY spectrum of 4	19
Fig 4-4	HMQC spectrum of 4	19
Fig 4-5	HMBC spectrum of 4	20
Fig 4-6	NOESY spectrum of 4	20
Fig 4-7	CD spectrum of 4	21
Fig 4-8	IR spectrum of 4	21
Fig 4-9	HRESIMS spectrum of 4	22
Fig 4-10	ESIMS spectrum of 4	22
Fig 5-1	¹ H NMR spectrum of 5	23
Fig 5-2	¹ H NMR spectrum of 6	23
Fig 5-3	COSY spectrum of 5	24
Fig 5-4	HMQC spectrum of 5	24
Fig 5-5	HMBC spectrum of 5	25
-	-	

Fig 5-6	NOESY spectrum of 5	25
Fig 5-7	CD spectrum of 5	
Fig 5-8	IR spectrum of 5	
Fig 5-9	HRESIMS spectrum of 5	27







Fig 1-2 DEPT spectrum of 1



Fig 1-4 HMQC spectrum of 1







Fig 1-6 NOESY spectrum of 1



Fig 1-7 CD spectrum of 1



Fig 1-8 CD spectrum of 1



Fig 1-9 HRESIMS spectrum of 1



Fig 1-10 ESIMS spectrum of 1



Fig 2-1 ¹H NMR spectrum of **2**



Fig 2-2 DEPT spectrum of 2







Fig 2-4 HMQC spectrum of 2







Fig 2-6 NOESY spectrum of 2



Fig 2-7 CD spectrum of 2



Fig 2-8 IR spectrum of 2







Fig 2-10 ESIMS spectrum of 2







Fig 3-2¹³CNMR spectrum of **3**







Fig 3-4 HMQC spectrum of 3







Fig 3-6 IR spectrum of **3**











Fig 3-9 ESIMS spectrum of 3







Fig 4-2¹³CNMR spectrum of 4







Fig 4-4 HMQC spectrum of 4







Fig 4-6 NOESY spectrum of 4



Fig 4-7 CD spectrum of 4



Fig 4-8 IR spectrum of 4















Fig 5-2 ¹HNMR spectrum of **6**







Fig 5-4 HMQC spectrum of 5







Fig 5-6 NOESY spectrum of 5



Fig 5-7 CD spectrum of 5



Fig 5-8 IR spectrum of 5



Fig 5-9 HRESIMS spectrum of 5